BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 27881565)

  • 1. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.
    Saito Y; Okada S; Ogawa H; Soejima H; Sakuma M; Nakayama M; Doi N; Jinnouchi H; Waki M; Masuda I; Morimoto T;
    Circulation; 2017 Feb; 135(7):659-670. PubMed ID: 27881565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
    Ogawa H; Nakayama M; Morimoto T; Uemura S; Kanauchi M; Doi N; Jinnouchi H; Sugiyama S; Saito Y;
    JAMA; 2008 Nov; 300(18):2134-41. PubMed ID: 18997198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
    JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Aspirin on Cancer Chemoprevention in Japanese Patients With Type 2 Diabetes: 10-Year Observational Follow-up of a Randomized Controlled Trial.
    Okada S; Morimoto T; Ogawa H; Sakuma M; Matsumoto C; Soejima H; Nakayama M; Doi N; Jinnouchi H; Waki M; Masuda I; Saito Y;
    Diabetes Care; 2018 Aug; 41(8):1757-1764. PubMed ID: 29909377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    ; Bowman L; Mafham M; Wallendszus K; Stevens W; Buck G; Barton J; Murphy K; Aung T; Haynes R; Cox J; Murawska A; Young A; Lay M; Chen F; Sammons E; Waters E; Adler A; Bodansky J; Farmer A; McPherson R; Neil A; Simpson D; Peto R; Baigent C; Collins R; Parish S; Armitage J
    N Engl J Med; 2018 Oct; 379(16):1529-1539. PubMed ID: 30146931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project.
    Uchiyama S; Ishizuka N; Shimada K; Teramoto T; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Minematsu K; Matsumoto M; Ikeda Y;
    Stroke; 2016 Jun; 47(6):1605-11. PubMed ID: 27165949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).
    Goicoechea M; de Vinuesa SG; Quiroga B; Verde E; Bernis C; Morales E; Fernández-Juárez G; de Sequera P; Verdalles U; Delgado R; Torres A; Arroyo D; Abad S; Ortiz A; Luño J
    Cardiovasc Drugs Ther; 2018 Jun; 32(3):255-263. PubMed ID: 29943364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
    N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).
    Sugawara M; Goto Y; Yamazaki T; Teramoto T; Oikawa S; Shimada K; Uchiyama S; Ando K; Ishizuka N; Murata M; Yokoyama K; Uemura Y; Ikeda Y;
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):299-311. PubMed ID: 30565155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).
    Bonaca MP; Goto S; Bhatt DL; Steg PG; Storey RF; Cohen M; Goodrich E; Mauri L; Ophuis TO; Ruda M; Špinar J; Seung KB; Hu D; Dalby AJ; Jensen E; Held P; Morrow DA; Braunwald E; Sabatine MS
    Circulation; 2016 Sep; 134(12):861-71. PubMed ID: 27576775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is Long-Term Low-Dose Aspirin Therapy Associated with Renal Dysfunction in Patients with Type 2 Diabetes? JPAD2 Cohort Study.
    Okada S; Morimoto T; Ogawa H; Sakuma M; Soejima H; Nakayama M; Jinnouchi H; Waki M; Akai Y; Ishii H; Saito Y;
    PLoS One; 2016; 11(1):e0147635. PubMed ID: 26808136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.
    Sleem A; Effron MB; Stebbins A; Wruck LM; Marquis-Gravel G; Muñoz D; Re RN; Gupta K; Pepine CJ; Jain SK; Girotra S; Whittle J; Benziger CP; Farrehi PM; Knowlton KU; Polonsky TS; Roe MT; Rothman RL; Harrington RA; Jones WS; Hernandez AF
    JAMA Cardiol; 2023 Nov; 8(11):1061-1069. PubMed ID: 37792369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex Difference in Effects of Low-Dose Aspirin on Prevention of Dementia in Patients With Type 2 Diabetes: A Long-term Follow-up Study of a Randomized Clinical Trial.
    Matsumoto C; Ogawa H; Saito Y; Okada S; Soejima H; Sakuma M; Masuda I; Nakayama M; Doi N; Jinnouchi H; Waki M; Morimoto T; ;
    Diabetes Care; 2020 Feb; 43(2):314-320. PubMed ID: 31801787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk.
    Okada S; Morimoto T; Ogawa H; Sakuma M; Soejima H; Nakayama M; Sugiyama S; Jinnouchi H; Waki M; Doi N; Horii M; Kawata H; Somekawa S; Soeda T; Uemura S; Saito Y;
    Circ J; 2013; 77(12):3023-8. PubMed ID: 24042256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.
    Fowkes FG; Price JF; Stewart MC; Butcher I; Leng GC; Pell AC; Sandercock PA; Fox KA; Lowe GD; Murray GD;
    JAMA; 2010 Mar; 303(9):841-8. PubMed ID: 20197530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
    Kim BJ; Kwon SU; Park JH; Kim YJ; Hong KS; Wong LKS; Yu S; Hwang YH; Lee JS; Lee J; Rha JH; Heo SH; Ahn SH; Seo WK; Park JM; Lee JH; Kwon JH; Sohn SI; Jung JM; Navarro JC; Kim HY; Kim EG; Kim S; Cha JK; Park MS; Nam HS; Kang DW;
    Stroke; 2020 Mar; 51(3):931-937. PubMed ID: 31856691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Use of Aspirin to Reduce the Risk of Thrombotic Events in Patients With End-Stage Renal Disease: Protocol for a Randomized Controlled Trial.
    Lemos Cerqueira T; Fartolino Guerrero A; Pérez Fermin CK; Wang R; Balbino EE; Breeze JL; Gonzalez Mego P; Argentina Silva D; Omer WE; Vandevelde NM
    JMIR Res Protoc; 2018 Aug; 7(8):e10516. PubMed ID: 30093367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events.
    Teramoto T; Shimada K; Uchiyama S; Sugawara M; Goto Y; Yamada N; Oikawa S; Ando K; Ishizuka N; Yamazaki T; Yokoyama K; Murata M; Ikeda Y
    Am Heart J; 2010 Mar; 159(3):361-369.e4. PubMed ID: 20211296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial.
    Saito Y; Morimoto T; Ogawa H; Nakayama M; Uemura S; Doi N; Jinnouchi H; Waki M; Soejima H; Sugiyama S; Okada S; Akai Y;
    Diabetes Care; 2011 Feb; 34(2):280-5. PubMed ID: 21270185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.
    Gallagher H; Dumbleton J; Maishman T; Whitehead A; Moore MV; Fuat A; Fitzmaurice D; Henderson RA; Lord J; Griffith KE; Stevens P; Taal MW; Stevenson D; Fraser SD; Lown M; Hawkey CJ; Roderick PJ
    Trials; 2022 Apr; 23(1):331. PubMed ID: 35449015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.